Trulieve (TRUL.C) has partnered with Morehouse School of Medicine to finance and conduct medical cannabis research and education.
“We have always placed our patients at the forefront of our business operations and are excited to partner with Morehouse School of Medicine…this partnership will enhance the cannabis community with the research and education necessary to facilitate the growth of a critical consumer industry and we look forward to collaborating with the tremendous team at the Morehouse School of Medicine,” said Trulieve CEO, Kim Rivers
Trulieve and Morehouse entered into a a mutually agreeable collaborative research, education, and development agreement. In accordance with the agreement, Trulieve Georgia will provide support to Morehouse’s medical cannabis-related research and development projects.
Additionally, the Company will provide course education opportunities and resources in cooperation with Morehouse. The two companies will be working together to design and participate in courses and seminars. These seminars will discuss medical cannabis production, purification, use, clinical outcomes, and commercialization. With a focus on providing enriching educational experiences, Trulieve and Morehouse are intent on creating opportunities for students via:
- Medical cannabis career fairs for students
- Internship programs for Morehouse and Atlanta University Center students
- creation of new minor or medical cannabis sub-specialty offerings in Morehouse’s graduate program
“When it comes to medical cannabis treatment and research as a whole, we have only scratched the surface of its potential and healing power…that’s why we could not be more excited about this partnership with Trulieve as we take steps to provide resources and education to the community, while also conducting research that will play a huge role in furthering the effectiveness and accuracy of cannabis treatment,” said Morehouse’s Vice President and Executive Dean, Sandra Harris-Hooker, Ph.D
Trulieve’s partnership with Morehouse aims to further research and develop a real-world data registry on medical cannabis. This will also include the exploration of cannabinoid receptor genetics, and research into the effects and potential of medical cannabis usage. Scientific jargon aside, the Company is focused on researching and providing evidence to support the beneficial uses of cannabis. This will enable Trulieve to fulfill their goal of developing personalized cannabis treatments.
Both Trulieve and Morehouse plan to partner with TruGenomix, a veteran-owned small business, founded and led by minorities, for gene sequencing research. The company was founded by Charles Cathlin, a man with both experience and credentials to his name. Regarding the company itself, TruGenomix relies on science via its TruGen-1 platform to provide objective information to help clinicians assess patients potentially suffering from PTSD.
Overall, its encouraging to see companies studying and promoting the practical uses of cannabis in the medical field.
Trulieve’s stock appears to be following an upward trend. The Company’s stock opened at $56.56 today and reached a high of $59.90. The stock price currently sits at $59.25.
